# US 2025/0144221 A1 · Methods and compounds for the treatment of genetic disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144221 A1
- Document ID: US20250144221A1
- Status: Published application
- Kind: A1
- Application number: 18/766,364
- Filed: 2024-07-08
- Published: 2025-05-08
- Earliest claimed: 2018-07-03
- Assignees: Design Therapeutics, Inc.
- Applicants: Design Therapeutics, Inc.
- Inventors: Aseem ANSARI; Pratik SHAH
- Web page: https://patentgrep.com/patent/US20250144221A1

## CPC

- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to compounds and methods which may be useful for modulating the expression of a target gene comprising a CGG trinucleotide repeat sequence and treating diseases and conditions in which the target gene plays an active role. The present disclosure provides compounds and methods for modulating the expression of fmr1 and fmr2, and provides compounds and methods for treating fragile X syndrome and fragile XE syndrome.

## Claims

### Claim at position 1

-188. (canceled)

### Claim 189

A method for modulating transcription of a gene comprising a trinucleotide repeat sequence CGG, the method comprising contacting a cell comprising the gene with an agent having a first terminus, a second terminus, and an oligomeric backbone, wherein:
(a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to the trinucleotide repeat sequence CGG;
(b) the second terminus comprises a protein-binding moiety capable of binding to a regulatory molecule that modulates an expression of the gene comprising the trinucleotide repeat sequence CGG; and
(c) the oligomeric backbone comprises a linker between the first terminus and the second terminus.

### Claim 190 (depends on 189)

The method of claim 189, wherein the DNA-binding moiety is a polyamide selected from a linear polyamide, a hairpin polyamide, a H-pin polyamide, an overlapped polyamide, a slipped polyamide, a cyclic polyamide, a tandem polyamide, and an extended polyamide.

### Claim 191 (depends on 189)

The method of claim 189, wherein the trinucleotide repeat comprises at least 20 repeats, at least 50 repeats, at least 100 repeats, at least 200 repeats, at least 500 repeats, or at least 1000 repeats.

### Claim 192 (depends on 189)

The method of claim 189, wherein the protein-binding moiety is capable of binding to a regulatory molecule that is selected from the group consisting of a CREB binding protein (CBP), a P300, an O-linked β-N-acetylglucosamine-transferase (OGT), a P300-CBP-associated-factor (PCAF), a histone methyltransferase, a histone demethylase, a chromodomain, a cyclin-dependent-kinase-9 (CDK9), a nucleosome-remodeling-factor (NURF), a bromodomain-PHD-finger-transcription-factor (BPTF), a ten-eleven-translocation-enzyme (TET), a methylcytosine-dioxygenase (TET1), a histone acetyltransferase (HAT), a histone deacetylase (HDAC), a host-cell-factor-1 (HCF1), an octamer-binding-transcription-factor (OCT1), a P-TEFb, a cyclin-T1, a PRC2, a DNA-demethylase, a helicase, an acetyltransferase, a histone-deacetylase, a bromodomain-containing protein and a methylated histone lysine protein.

### Claim 193 (depends on 189)

The method of claim 189, wherein the protein-binding moiety is selected from the group consisting of a bromodomain inhibitor, a BPTF inhibitor, a methylcytosine dioxygenase inhibitor, a DNA demethylase inhibitor, a helicase inhibitor, an acetyltransferase inhibitor, a histone deacetylase inhibitor, a CDK-9 inhibitor, a positive transcription elongation factor inhibitor, and a polycomb repressive complex inhibitor.

### Claim 194 (depends on 189)

The method of claim 189, wherein the second terminus does not comprises a moiety that binds to a bromodomain protein.

### Claim 195 (depends on 189)

The method of claim 189, wherein the protein-binding moiety does not comprise JQ1, iBET762, OTX015, RVX208, or AU1.

### Claim 196 (depends on 189)

The method of claim 189, wherein the protein-binding moiety binds the regulatory molecule with an affinity of less than 200 nM.

### Claim 197 (depends on 189)

The method of claim 189, wherein the linker has a length of less than about 50 Angstroms.

### Claim 198 (depends on 189)

The method of claim 189, wherein the linker comprises between 5 and 50 chain atoms.

### Claim 199 (depends on 189)

The method of claim 189, wherein the gene is FMR1 or FMR2.

### Claim 200 (depends on 199)

The method of claim 199, wherein the DNA-binding moiety is capable of selectively binding to a CGG nucleotide repeat sequence of FMR1 or FMR2.

### Claim 201 (depends on 199)

The method of claim 199, wherein the method comprises decreasing FMR1 or FMR2 expression.

### Claim 202 (depends on 201)

The method of claim 201, wherein the method comprises a 20%, 50%, 80%, 90%, 95%, or 99% decrease in expression of FMR1 or FMR2.

### Claim 203 (depends on 189)

The method of claim 189, wherein the method further comprises treating a disease mediated by transcription of an allele of FMR1 or FMR2 comprising the CGG nucleotide repeat sequence in a patient in need thereof.

### Claim 204 (depends on 203)

The method of claim 203, wherein the disease is fragile X syndrome, fragile XE or FXTAS.
